These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33064276)

  • 41. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
    Pestieau SR; Schnake KJ; Stuart OA; Sugarbaker PH
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):269-76. PubMed ID: 11320672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
    Van Nuland M; Rosing H; Thijssen B; Burgers JA; Huitema ADR; Marchetti S; Schellens JHM; Beijnen JH
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):929-937. PubMed ID: 31970932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
    Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
    Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
    Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
    Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of bioactive gemcitabine-D-Lys
    Sayyad N; Vrettos EI; Karampelas T; Chatzigiannis CM; Spyridaki K; Liapakis G; Tamvakopoulos C; Tzakos AG
    Eur J Med Chem; 2019 Mar; 166():256-266. PubMed ID: 30716713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical pharmacokinetics of capecitabine.
    Reigner B; Blesch K; Weidekamm E
    Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
    Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
    Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.
    Eisbruch A; Shewach DS; Bradford CR; Littles JF; Teknos TN; Chepeha DB; Marentette LJ; Terrell JE; Hogikyan ND; Dawson LA; Urba S; Wolf GT; Lawrence TS
    J Clin Oncol; 2001 Feb; 19(3):792-9. PubMed ID: 11157033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
    Galmarini CM; Warren G; Kohli E; Zeman A; Mitin A; Vinogradov SV
    Mol Cancer Ther; 2008 Oct; 7(10):3373-80. PubMed ID: 18852140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
    Mynhardt C; Damelin LH; Jivan R; Peres J; Prince S; Veale RB; Mavri-Damelin D
    J Cell Biochem; 2018 Jan; 119(1):1193-1203. PubMed ID: 28722177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells.
    Cronauer MV; Klocker H; Talasz H; Geisen FH; Hobisch A; Radmayr C; Böck G; Culig Z; Schirmer M; Reissigl A; Bartsch G; Konwalinka G
    Prostate; 1996 Mar; 28(3):172-81. PubMed ID: 8628720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.
    Schirmer M; Stegmann AP; Geisen F; Konwalinka G
    Exp Hematol; 1998 Dec; 26(13):1223-8. PubMed ID: 9845378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
    Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
    Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
    Shord SS; Faucette SR; Gillenwater HH; Pescatore SL; Hawke RL; Socinski MA; Lindley C
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):328-36. PubMed ID: 12721761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
    Rizzuto I; Ghazaly E; Peters GJ
    Pharmacogenomics; 2017 Jun; 18(9):911-925. PubMed ID: 28594276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1997 May; 24(7):761-70. PubMed ID: 9170512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.